Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aethlon Medical ( (AEMD) ) just unveiled an announcement.
On August 13, 2025, Aethlon Medical announced its financial results for the fiscal first quarter ending June 30, 2025, and provided a corporate update. The company reported significant progress in its Australian Hemopurifier cancer trial, with the first cohort completed without serious adverse events, and an amended protocol to broaden patient eligibility. Aethlon also highlighted a 31.6% reduction in operating expenses, enhancing operational efficiency. Additionally, the company decided not to proceed with an oncology trial in India to focus resources on the ongoing Australian trial. Preclinical studies showed promising results for the Hemopurifier’s broader applications, including Long COVID, supporting its potential use in various EV-associated diseases.
The most recent analyst rating on (AEMD) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Aethlon Medical stock, see the AEMD Stock Forecast page.
Spark’s Take on AEMD Stock
According to Spark, TipRanks’ AI Analyst, AEMD is a Underperform.
Aethlon Medical’s overall stock score is low due to significant financial challenges, including persistent losses and cash flow issues. The technical indicators suggest negative momentum, and the valuation is unattractive given the negative P/E ratio and lack of dividends. While the earnings call presented some positive strategic efforts, such as cost reduction and trial advancements, the hurdles in clinical trials and financial constraints weigh heavily on the stock’s outlook.
To see Spark’s full report on AEMD stock, click here.
More about Aethlon Medical
Aethlon Medical, Inc. is a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. The company is involved in clinical trials and preclinical research, with a market focus on oncology and infectious disease treatment.
Average Trading Volume: 261,185
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.26M
Learn more about AEMD stock on TipRanks’ Stock Analysis page.